Clinical trial research agreement Agreed schedule 4 or 7 clause amendments

Size: px
Start display at page:

Download "Clinical trial research agreement Agreed schedule 4 or 7 clause amendments"

Transcription

1 Clinical trial research agreement Agreed schedule 4 or 7 clause amendments Medicines Australia and Medical Technology Association of Australia templates The sponsors in the table have agreed clauses for inclusion into Schedule 4 or 7 of the Medicines Australia Clinical Trial Research Agreements or the Medical Technology Association of Australia Clinical Investigation Research Agreements. Queensland Health Research Governance Office/rs have a copy of the agreed clauses. Sponsor Template Clinical Research Organisation () Version AbbVie Phase IV Phase IV April 2014 AbbVie Standard March 2013 AbbVie & Genentech Standard September 2013 Abivax SA Novotech Australia Pty December 2014 Acerta Pharma LLC Novotech Australia Pty December 2014 Alexion Pharmaceuticals Standard April 2014 Alexion Pharmaceuticals Phase IV April 2014 Allergan Inc Standard May 2014 Allos EMAS Pharma Pty July 2012 Amgen Australia Pty Standard April 2013 Amgen Australia Pty Standard August 2014 Amgen Australia Pty Standard December 2014 ANZ Breast Cancer Trials Group (ANZBCTG) ANZ Breast Cancer Trials Group (ANZBCTG) December 2014 ANZIC-Research Centre, Monash University CRG December 2013 (SPICE Study)

2 Aragon Pharmaceuticals Pty Pharmaceutical Research Associates (PRA) February 2015 Ardea Biosciences Novotech Australia Pty March 2013 Arena Pharmaceuticals Inc JAAD Enterprises August 2014 Clinical Network Services (CNS) February 2013 Quintiles Pty August 2011 ICON November 2011 INC Research Australia Pty February 2012 Astex Pharmaceuticals Pharmaceutical Research Associates (PRA) December 2014 Auspex Pharmaceuticals Inc INC Research Australia Pty September 2014 Australian Leukaemia & Lymphoma Group (ALLG) Australian Red Cross Blood Service CRG November 2012 CRG November 2014 (ARCBS Owned IP) Australian Red Cross Blood Service CRG November 2014 (Joint IP) Avid Radiopharmaceuticals Neuroscience Trials Australia February 2014 Bayer Australia Phase IV July 2013 Biogen Idec Phase IV November 2013 Biogen Idec Standard November 2013 BioMarin Pharmaceuticals Pacific Clinical Research Group September 2013 Biota Standard April 2013 Biotronik Australia Standard June 2012 Boehringer Ingelheim Pty Standard February 2015 Eli Lilly Parexel, Quintiles or Covance September 2014 Eli Lilly Phase IV September 2014 Eli Lilly Standard September 2014 EMR Associates Pty EMR Associates Pty October 2013 Clinical trial research agreement Agreed schedule 4 or 7 clause amendments March

3 F.Hoffman-La Roche Quintiles Pty March 2013 (GO27878) F.Hoffman-La Roche & Genentech Standard August 2014 Flexpharma Neuroscience Trials Australia November 2014 Fondazione Michelangelo Breast Cancer Clinical Trials Unit June 2013 GlaxoSmithKline Standard September 2014 (Novartis announcement only) Global Genomics Group LLC Barons Medical Consulting Pty November 2013 Idenix Pharma Inc Quintiles Pty July 2014 Incyte Corporation Medpace Australia Pty February 2013 inventive Health clinical inventive Health clinical April 2013 Ipsen Pty Phase IV January 2015 Janssen Research and Development PharmaNet Pty September 2013 Janssen-Cilag Pty Standard June 2013 Johnson & Johnson Pty Standard July 2013 Karyopharm Inc Novotech Australia Pty September 2014 Kyowa Hakko Kirin Pharma Inc Medpace Australia Pty July 2014 Leo Pharma Pty Standard December 2014 Lexicon Pharmaceuticals Inc INC Research Australia Pty May 2013 Lundbeck Standard February 2014 Marinus Pharmaceuticals Neuroscience Trials Australia November 2014 Merck Serono Australia Pty Merck Serono Australia Pty Standard December 2013 Quintiles Pty January 2014 Merck Sharp & Dohme Phase IV May 2014 Millennium Pharmaceuticals ICON December 2012 Clinical trial research agreement Agreed schedule 4 or 7 clause amendments March

4 Monash University CRG October 2013 (Balanced Study) New York University CRG April 2013 (ISCHEMIA Study) Population Health Research Institute (PHRI) CRG December 2014 Population Health Research Institute (PHRI) CRG TOTAL Study PTC Therapeutics PPD Australia Pty April 2013 Quintiles Pty Quintiles Pty April 2013 ( ABAC) Quintiles Pty Standard April 2013 (Std ABAC) Quintiles Pty Phase IV August 2014 Quintiles Pty Quintiles Pty November 2014 (Third Party) Regeneron Pharmaceuticals, Inc PPD Australia Pty January 2015 Rigel Pharmaceuticals Inc INC Research Australia Pty December 2014 Roche Products Pty February 2013 Roche Products Pty Standard February 2013 sanofi-aventis Phase IV October 2013 sanofi-aventis Standard September 2013 Servier Laboratories (Aust.) Pty Servier Laboratories (Aust.) Pty Standard April 2013 Standard January 2014 (QUALIFY Study) Shionogi Inc Medpace Australia Pty September 2013 Southern Star Research Southern Star Research January 2015 St. Jude Medical MTAA Standard July 2014 St. Jude Medical Standard July 2014 Stryker Australia Pty MTAA Standard August 2014 Sydney Local Health District CRG August 2014 (QLD version) Clinical trial research agreement Agreed schedule 4 or 7 clause amendments March

5 Takeda Development Centre Asia Pte. Quintiles Pty March 2014 TauRx Worldwide Clinical Trials September 2014 The George Clinical Pty The George Clinical Pty September 2014 The George Institute for Global Health The George Institute for Global Health The Princess Alexandra Hospital CRG October 2013 CRG November 2014 CRG July 2014 (Pomalidomide Study) UCB Australia Pty Standard July 2012 University of California CRG Neuroscience Trials Australia March 2013 University of Queensland CRG SMARRT Study Vertex September 2013 Washington University Quintiles Pty October 2013 Women's and Children's Health Network CRG July 2013 Clinical trial research agreement Agreed schedule 4 or 7 clause amendments March

Outcomes of Monitoring Committee Reviews. Medicines Australia Code of Conduct

Outcomes of Monitoring Committee Reviews. Medicines Australia Code of Conduct Outcomes of Monitoring Committee Reviews Medicines Australia Code of Conduct 1 Medicines Australia ABN 23 126 990 001 Level 1, 16 Napier Close Deakin ACT 2600 Phone: 02 6122 8500 Fax: 02 6122 8555 Web:

More information

The Hong Kong Association of The Pharmaceutical Industry

The Hong Kong Association of The Pharmaceutical Industry The Hong Kong Association of The Pharmaceutical Industry UNIT A, 20/F., TIMES MEDIA CENTRE, FAX: (852) 2865 6283 WEBSITE: www. hkapi.hk Position Paper on the Pharmacy and Poisons (Amendment) Bill 2014

More information

As featured in. Orphan disease specialists find home with Big Pharma.

As featured in. Orphan disease specialists find home with Big Pharma. Orphan disease specialists find home with Big Pharma. By Maura Musciacco Senior Analyst January 2013 Tumbling over the patent cliff, many big pharma companies are being forced to find new strategies for

More information

KEEPING CLINICAL TRIALS IN AUSTRALIA

KEEPING CLINICAL TRIALS IN AUSTRALIA OCCASIONAL PAPER SERIES KEEPING CLINICAL TRIALS IN AUSTRALIA WHY ACTION IS NEEDED NOW OCCASIONAL PAPER SERIES > Medicines Australia is producing Occasional Papers to promote a contest of ideas, thought

More information

6 th Proactive GCP Compliance Effective Risk- Based Approaches for Optimizing Clinical Quality

6 th Proactive GCP Compliance Effective Risk- Based Approaches for Optimizing Clinical Quality 6 th Proactive GCP Compliance Effective Risk- Based Approaches for Optimizing Clinical Quality March 24-25, 2015 Wyndham Philadelphia Historic District, Philadelphia, PA www.exlevents.com/gcp Sponsors

More information

CHAPTER FOUR: CLINICAL TRIAL COST AND FUNDING... 30

CHAPTER FOUR: CLINICAL TRIAL COST AND FUNDING... 30 CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THE STUDY... 1 INTENDED AUDIENCE... 2 METHODOLOGY... 2 ANALYST CREDENTIALS... 2 SCOPE OF REPORT... 2 INFORMATION SOURCES...

More information

Oracle Buys Phase Forward Expands Oracle s solutions for the life sciences and healthcare industries

Oracle Buys Phase Forward Expands Oracle s solutions for the life sciences and healthcare industries Oracle Buys Phase Forward Expands Oracle s solutions for the life sciences and healthcare industries April 16, 2010 Oracle is currently reviewing the existing Phase Forward product roadmap and will be

More information

Metastatic Breast Cancer - Pipeline Review, Q1 2011

Metastatic Breast Cancer - Pipeline Review, Q1 2011 Brochure More information from http://www.researchandmarkets.com/reports/1524592/ Metastatic Breast Cancer - Pipeline Review, Q1 2011 Description: Metastatic Breast Cancer - Pipeline Review, Q1 2011 Summary

More information

ehealthinsight Series: Online Patient Recruitment Strategies

ehealthinsight Series: Online Patient Recruitment Strategies A Datamonitor report ehealthinsight Series: Online Patient Recruitment Strategies Published: May-08 Product Code: Providing you with: Overview of benefits and drawbacks of online Analysis of online patient

More information

Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019

Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019 Brochure More information from http://www.researchandmarkets.com/reports/3453273/ Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019 Description: About non-small cell lung cancer therapeutics

More information

Trends in the pharmaceutical industry and potential impact on future innovation and access to medicines

Trends in the pharmaceutical industry and potential impact on future innovation and access to medicines Trends in the pharmaceutical industry and potential impact on future innovation and access to medicines The R&D Process: Long, Complex, and Costly Average cost of R&D is $1.2 Billion The Current Challenge

More information

Rx-360 An International Pharmaceutical Supply Chain Consortium

Rx-360 An International Pharmaceutical Supply Chain Consortium Rx-360 An International Pharmaceutical Supply Chain Consortium Overview Rx-360 and the Audit Sharing Program September 2011 Rx-360 Members (Continuously updated list at www.rx-360.org) Manufacturers (24)

More information

Avoca s Quality Metrics Consulting Service Offering

Avoca s Quality Metrics Consulting Service Offering Avoca s Quality Metrics Consulting Service Offering Avoca s Quality Metrics Consulting The Challenge Biopharmaceutical companies and CROs struggle in defining how best to utilize quality metrics to optimize

More information

The Global Biotech Industry: Challenges & Opportunities Michael S. Rosen Rosen Bioscience Strategies

The Global Biotech Industry: Challenges & Opportunities Michael S. Rosen Rosen Bioscience Strategies The Global Biotech Industry: Challenges & Opportunities Michael S. Rosen Rosen Bioscience Strategies Greetings from Chicago! Beaches Yes! Pharma Beginnings! Bogota 1974 Selling Drugs in Colombia Global

More information

Pharma working capital performance highly variable

Pharma working capital performance highly variable April 2014 Pharma working capital performance highly variable 41 Billion in Excess Working Capital We last completed this survey in 2012. We expected that there would be a broad improvement across the

More information

e-labeling : innovation for patient or regulation nightmare Pharmapack Feb, 11 th, 2015

e-labeling : innovation for patient or regulation nightmare Pharmapack Feb, 11 th, 2015 e-labeling : innovation for patient or regulation nightmare Pharmapack Feb, 11 th, 2015 PHARMAPACK 2015 1 Mobile health x2 30 months 100 000 mapps Source: research2guidance, mhealth App Market Report 2013-2017

More information

EXPERT SPEAKER PANEL. Director, Portfolio Management Biologics Dr. Reddy s Laboratories. CEO Enrich. Executive Program Director ImmunoGen

EXPERT SPEAKER PANEL. Director, Portfolio Management Biologics Dr. Reddy s Laboratories. CEO Enrich. Executive Program Director ImmunoGen www.americanleaders.com 8 th Project and Portfolio Management for Pharma & Biotech Leveraging the Catalysts of Portfolio Success October 6-7, 2015 Hyatt Regency Boston Post-show report EXPERT SPEAKER PANEL

More information

Toulouse University, Hôpital Larrey, Toulouse, France

Toulouse University, Hôpital Larrey, Toulouse, France 2177 Long-term Safety and Tolerability of Apremilast in Patients With Psoriasis: Analysis of Two Phase 3, Randomized, Controlled Trials (ESTEEM 1 and 2) Kristian Reich, MD 1 ; Kim Papp, MD 2 ; Kenneth

More information

CHEM-E4140 Selectivity 12. Pharma Business

CHEM-E4140 Selectivity 12. Pharma Business CHEM-E4140 Selectivity 12. Pharma Business Prof. Ari Koskinen Laboratory of Organic Chemistry C318 Pharma Business Total volume ca 1100 G$ (Shell 421G$; Walmart 486G$; Toyota 252 G$). Annually approx 25

More information

Manufacturer of drug substance

Manufacturer of drug substance Original s and Biosimilars (marketing authorizations in the EU) Date: January 2016 1) Somatropin s ORIGINAL PRODUCTS: Authorization Genentech Genotropin Somatropin Pharmacia/ Pfizer E. coli Humatrope Somatropin

More information

Decision Matrix: Selecting a CRM Vendor in the Pharmaceutical Market (Competitor Focus)

Decision Matrix: Selecting a CRM Vendor in the Pharmaceutical Market (Competitor Focus) A Datamonitor report Decision Matrix: Selecting a CRM Vendor in the Pharmaceutical Market (Competitor Focus) Published: Oct 07 Product Code: DMTC2133 Providing you with: Identifies which technology vendors

More information

EU Clinical Trials Register

EU Clinical Trials Register EU Clinical Trials Register Sponsor Contact Information Abbott Laboratories Ltd Abbott House, Vanwall Business Park, Vanwall Road, Maidenhead, Berkshire SL6 4XE UK Telephone number +44 1628 644475 euclinicaltrials@abbott.com

More information

December 17, 2014 HOW PHARMA MARKETERS FIND AND SELECT DIGITAL MARKETING AGENCIES

December 17, 2014 HOW PHARMA MARKETERS FIND AND SELECT DIGITAL MARKETING AGENCIES December 17, 2014 HOW PHARMA MARKETERS FIND AND SELECT DIGITAL MARKETING AGENCIES by Dennis van Rooij with Tim van Tongeren EXECUTIVE SUMMARY More than half of pharma marketers don t or can t leverage

More information

The Role Of Industry in the Australian Clinical Trials Sector

The Role Of Industry in the Australian Clinical Trials Sector Mitch Kirkman, Development QA Manager Australian Clinical Trials Alliance Symposium 09 October 2015 CORP0270 September 2015 Global Clinical Development Local Clinical Trials Australian Medical Research

More information

EFPIA Position Paper on REACH. Executive Summary. Position Paper. Draft Final. Author: EFPIA Date: October 2015 Version: Final

EFPIA Position Paper on REACH. Executive Summary. Position Paper. Draft Final. Author: EFPIA Date: October 2015 Version: Final Draft Final EFPIA Position Paper on REACH Author: EFPIA Date: October 2015 Version: Final Position Paper Executive Summary An increasing number of substances used in the pharmaceutical manufacturing process

More information

Pertuzumab in Trastuzumab- Treated, Advanced HER2-Positive Breast Cancer

Pertuzumab in Trastuzumab- Treated, Advanced HER2-Positive Breast Cancer Pertuzumab in Trastuzumab- Treated, Advanced HER2-Positive Breast Cancer For more visit ResearchToPractice.com/5MJC CME INFORMATION OVERVIEW OF ACTIVITY Each year, thousands of clinicians and basic scientists

More information

TABLE 2 RECOGNIZED AND POTENTIAL AUTOIMMUNE DISEASES AND THE SYSTEMS THEY EFFECT,

TABLE 2 RECOGNIZED AND POTENTIAL AUTOIMMUNE DISEASES AND THE SYSTEMS THEY EFFECT, CHAPTER ONE: INTRODUCTION... 1 REASONS FOR DOING THE STUDY... 1 STUDY GOALS AND OBJECTIVES... 1 SCOPE OF REPORT... 2 INTENDED AUDIENCE... 2 METHODOLOGIES AND INFORMATION SOURCES... 2 ANALYST CREDENTIALS...

More information

The 2015 Avoca Report. Clinical Development Innovation. Sponsor and Provider Views on Innovation in Outsourced Clinical Development

The 2015 Avoca Report. Clinical Development Innovation. Sponsor and Provider Views on Innovation in Outsourced Clinical Development The 2015 Avoca Report Clinical Development Innovation Sponsor and Provider Views on Innovation in Outsourced Clinical Development Contents Section Slides Research Overview 3-5 Respondent Demographics 6-9

More information

APAC CRO Market A deep dive into the trends transforming APAC CRO industry. P86A-52 June 2015

APAC CRO Market A deep dive into the trends transforming APAC CRO industry. P86A-52 June 2015 APAC CRO Market A deep dive into the trends transforming APAC CRO industry June 2015 Table of Contents Section Slide Numbers Executive Summary 10 Key Findings 11 Total CRO Market Size By Stages of Clinical

More information

Sharing Industry Clinical Trial Data: Improving Public Health While Maintaining the Oversight Relationship Between Regulator and Sponsor

Sharing Industry Clinical Trial Data: Improving Public Health While Maintaining the Oversight Relationship Between Regulator and Sponsor Sharing Industry Clinical Trial Data: Improving Public Health While Maintaining the Oversight Relationship Between Regulator and Sponsor Steven Snapinn SCT/QSPI/FDA Workshop Innovations in the Science

More information

ENAR Spring Meeting With IMS & Sections of ASA

ENAR Spring Meeting With IMS & Sections of ASA ENAR Spring Meeting With IMS & Sections of ASA March 6-9 2016 JW MARRIOTT AUSTIN AUSTIN, TX Sponsorship, Exhibitor, & Advertising Opportunities Sponsorship, Exhibitor, & Advertising Opportunities On behalf

More information

ENAR Spring Meeting With IMS & Sections of ASA

ENAR Spring Meeting With IMS & Sections of ASA ENAR Spring Meeting With IMS & Sections of ASA March 6-9 2016 JW MARRIOTT AUSTIN AUSTIN, TX Sponsorship, Exhibitor, & Advertising Opportunities Sponsorship, Exhibitor, & Advertising Opportunities On behalf

More information

In the largest and perhaps the most ambitious collaborative

In the largest and perhaps the most ambitious collaborative FEATURES THE BIRTH OF TRANSCELERATE BIOPHARMA, INC. Revolution in Clinical Research Partnerships by Dalvir Gill and Garry Neil In the largest and perhaps the most ambitious collaborative effort ever initiated

More information

Global Monoclonal Antibodies Pipeline Insight 2015

Global Monoclonal Antibodies Pipeline Insight 2015 Brochure More information from http://www.researchandmarkets.com/reports/3113388/ Global Monoclonal Antibodies Pipeline Insight 2015 Description: Ever since the Nobel Prize was bestowed on the person who

More information

CODE FOR DISCLOSURE OF TRANSFERS OF VALUE BY PHARMACEUTICAL COMPANIES TO HEALTHCARE PROFESSIONALS AND HEALTH ORGANIZATIONS

CODE FOR DISCLOSURE OF TRANSFERS OF VALUE BY PHARMACEUTICAL COMPANIES TO HEALTHCARE PROFESSIONALS AND HEALTH ORGANIZATIONS CODE FOR DISCLOSURE OF TRANSFERS OF VALUE BY PHARMACEUTICAL COMPANIES TO HEALTHCARE PROFESSIONALS AND HEALTH ORGANIZATIONS Adopted November 2013, in force since 1 st of January 2014. INTRODUCTION The Association

More information

Shifting paths of pharmaceutical innovation: Implications for the global pharmaceutical industry

Shifting paths of pharmaceutical innovation: Implications for the global pharmaceutical industry Shifting paths of pharmaceutical innovation: Implications for the global pharmaceutical industry Tariq Sadat PhD Candidate School of Economics, Finance and Marketing, RMIT University, Australia Roslyn

More information

Tuas Biomedical Park

Tuas Biomedical Park Tuas Biomedical Park About Tuas Biomedical Park Tuas Biomedical Park symbolises JTC s commitment in developing a world-class manufacturing hub for the biomedical industry. The park is located in Tuas View,

More information

CONTRACT RESEARCH ORGANIZATION INDUSTRY OVERVIEW

CONTRACT RESEARCH ORGANIZATION INDUSTRY OVERVIEW CONTRACT RESEARCH ORGANIZATION INDUSTRY OVERVIEW April 2014 Investment banking services are provided by Harris Williams LLC, a registered broker-dealer and member of FINRA and SIPC, and Harris Williams

More information

Manufacturer of drug substance

Manufacturer of drug substance Original s and Biosimilars (marketing authorizations in the EU) Date: December 2016 1) Somatropin s ORIGINAL PRODUCTS: Marketing Authorization Genentech Genotropin Somatropin Pharmacia/ Pfizer E. coli

More information

Pharma working capital leaves room for improvement

Pharma working capital leaves room for improvement October 2012 Pharma working capital leaves room for improvement 50.7 Billion in Excess Working Capital Ten years ago it was not unusual to be asked why working capital mattered to a pharmaceutical company.

More information

2011 Avoca Clinical Outsourcing and Relationship Management Survey: Sponsor Needs and Challenges in Clinical Development Outsourcing

2011 Avoca Clinical Outsourcing and Relationship Management Survey: Sponsor Needs and Challenges in Clinical Development Outsourcing 2011 Avoca Clinical Outsourcing and Relationship Management Survey: Sponsor Needs and Challenges in Clinical Development Outsourcing Executive Summary April 2011 Introduction Introduction Each year, The

More information

Biopharmaceutical Raw Materials throughout the Product Lifecycle

Biopharmaceutical Raw Materials throughout the Product Lifecycle February 27 March 2, 2012 Hilton San Diego Bayfront San Diego, CA Monday Tuesday Programming: IBC s 17th International Process & Analytical Assay Validation IBC s 8th International Outsourcing Manufacturing

More information

PPRS 2014 analysis of growth in spend of branded medicines. DH Leading the nation s health and care

PPRS 2014 analysis of growth in spend of branded medicines. DH Leading the nation s health and care PPRS 2014 analysis of growth in spend of branded medicines March 2015 Executive Summary IMS Health data shows growth in spend in 2014 (compared to 2013) of 8.2% on branded medicines. This is higher than

More information

The Top 10 Contract Research Organizations

The Top 10 Contract Research Organizations OUTSOURCING The Top 10 Contract Research Organizations Positioning, performance and SWOT analyses Table of Contents Copyright 2009 Business Insights Ltd This Management Report is published by Business

More information

1) SCOPE OF THE PROGRAM

1) SCOPE OF THE PROGRAM CALL FOR PROJECTS 2015/16 CANADA/GERMANY JOINT PROGRAM DEADLINE: 15 TH JANUARY 2016 1) SCOPE OF THE PROGRAM The main goal of the Canada/Germany joint program is to strengthen research in Canada and Germany

More information

Malignant Mesothelioma - Pipeline Review, H1 2015

Malignant Mesothelioma - Pipeline Review, H1 2015 Brochure More information from http://www.researchandmarkets.com/reports/3308784/ Malignant Mesothelioma - Pipeline Review, H1 2015 Description: Malignant Mesothelioma - Pipeline Review, H1 2015 Summary

More information

PRAC recommendations on signals

PRAC recommendations on signals 25 June 2015 EMA/PRAC/383371/2015 Pharmacovigilance Risk Assessment Committee Adopted at the PRAC meeting of 8-11 June 2015 This document provides an overview of the recommendations adopted by the Pharmacovigilance

More information

In-depth analysis of the report is based on propriety databases, primary and secondary research and inhouse analysis by a team of experts.

In-depth analysis of the report is based on propriety databases, primary and secondary research and inhouse analysis by a team of experts. Brochure More information from http://www.researchandmarkets.com/reports/1882193/ Top 20 Contract Research Organizations (CRO) - Asia-Pacific, Especially India and China, Positioned to Benefit from Rising

More information

Multiple Sclerosis Treatments: World Market Outlook to 2011

Multiple Sclerosis Treatments: World Market Outlook to 2011 Brochure More information from http://www.researchandmarkets.com/reports/2860814/ Multiple Sclerosis Treatments: World Market Outlook to 2011 Description: Multiple sclerosis (MS) is a chronic demyelinating

More information

Stakeholder Perspectives: Mild Cognitive Impairment and Dementia

Stakeholder Perspectives: Mild Cognitive Impairment and Dementia A Datamonitor In-Depth Analysis Stakeholder Perspectives: Mild Cognitive Impairment and Dementia Aricept in Race to Pioneer Unexplored Markets Published: Aug-03 Product Code: DMHC1924 Why buy this analysis?

More information

Cancer Drugs Data, Analysis and Forecasts to 2023

Cancer Drugs Data, Analysis and Forecasts to 2023 Cancer Drugs Data, Analysis and Forecasts to 2023 Pharmaceutical, Commercial & Strategic Developments in the Global Cancer Drugs Market to 2023 GMRData.com 1. Executive Summary 1.1. Cancer Drugs Market

More information

To know more about Pharmacovigilance and Clinical Trials Data Management

To know more about Pharmacovigilance and Clinical Trials Data Management To know more about Pharmacovigilance and Clinical Trials Data Management 1. What is Pharmacovigilance? Pharmacovigilance (PV) is the pharmacological science related to the detection, assessment, understanding

More information

Orphan drugs program. Discussion paper. May 2015

Orphan drugs program. Discussion paper. May 2015 Orphan drugs program Discussion paper About the Therapeutic Goods Administration (TGA) The Therapeutic Goods Administration (TGA) is part of the Australian Government Department of Health, and is responsible

More information

Key Findings. Use this report to... The Top 10 Contract Research Organizations

Key Findings. Use this report to... The Top 10 Contract Research Organizations Key Findings The global CRO industry valued $18bn in 2008, an increase of 14% over 2007. The CRO market will grow at an annual rate of 14% over the 2009 13 period. Quintiles leads the global CRO market

More information

M&A und Allianzen in Life Science Aktuelle Entwicklungen und Trends

M&A und Allianzen in Life Science Aktuelle Entwicklungen und Trends M&A und Allianzen in Life Science Aktuelle Entwicklungen und Trends Symposium Life Science am Kapitalmarkt Frankfurt, 3. Juni 28 Global biotech industry Strong growth in most areas but Visible product

More information

The Next Wave of Psoriasis Drug Programs: Targeting IL-17 and IL-23 PAMELA SPICER ANALYST, CNS, AUTOIMMUNE/INFLAMMATION, OPHTHALMOLOGY

The Next Wave of Psoriasis Drug Programs: Targeting IL-17 and IL-23 PAMELA SPICER ANALYST, CNS, AUTOIMMUNE/INFLAMMATION, OPHTHALMOLOGY The Next Wave of Psoriasis Drug Programs: Targeting IL-17 and IL-23 PAMELA SPICER ANALYST, CNS, AUTOIMMUNE/INFLAMMATION, OPHTHALMOLOGY 2 Psoriasis is a chronic inflammatory condition that primarily affects

More information

PG Diploma in Clinical Research, Pharmacovigilance, Regulatory and Clinical Data Management

PG Diploma in Clinical Research, Pharmacovigilance, Regulatory and Clinical Data Management PG Diploma in Clinical Research, Pharmacovigilance, Regulatory and Clinical Data Management Contact: +91 9886735658, 080 28411665 ext 5103 Email: crtraining@avesthagen.com PG Diploma In Clinical Research,

More information

Role of Competition in the Pharmaceutical Sector and its benefits for Consumers

Role of Competition in the Pharmaceutical Sector and its benefits for Consumers Role of Competition in the Pharmaceutical Sector and its benefits for Consumers Seventh United Nations Conference to review the UN Set on Competition Policy Wednesday 8 th July 2015 Pradeep S Mehta CUTS

More information

LIGHTHOUSE. In-process monitoring of headspace oxygen levels in parenteral containers. Application Note 102

LIGHTHOUSE. In-process monitoring of headspace oxygen levels in parenteral containers. Application Note 102 In-process monitoring of headspace oxygen levels in parenteral containers In-process monitoring of headspace oxygen levels in parenteral containers Introduction The need to monitor headspace oxygen levels

More information

David Owen Licensing & IP business models. 27th of May, Paris

David Owen Licensing & IP business models. 27th of May, Paris David Owen Licensing & IP business models 27th of May, Paris LICENSING STRATEGY The key decision factors? Exclusive / non-exclusive? THESIS TTOs could and should make greater use of non-exclusive licensing

More information

Pharmacovigilance Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013-2019 Single User License: US $ 4595

Pharmacovigilance Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013-2019 Single User License: US $ 4595 Transparency Market Research Pharmacovigilance Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013-2019 Single User License: US $ 4595 Buy Now Request Sample Published Date:

More information

Main Conference Agenda

Main Conference Agenda Sponsored by: (Co-located with Bioequivalence: Intersection between Science & Regulatory Conference) Main Conference Agenda Day One Wednesday, November 5 th, 2014 7:30 Registration Opens & Continental

More information

Sequential Parallel Comparison Design (SPCD) in CNS Clinical Trials

Sequential Parallel Comparison Design (SPCD) in CNS Clinical Trials Sequential Parallel Comparison Design (SPCD) in CNS Clinical Trials Maurizio Fava, MD Executive Vice Chair, Department of Psychiatry Director, Depression Clinical and Research Program Massachusetts General

More information

APAC Contract Research Organisation (CRO) Market

APAC Contract Research Organisation (CRO) Market Brochure More information from http://www.researchandmarkets.com/reports/3308444/ APAC Contract Research Organisation (CRO) Market Description: The research service presents an overview and analysis of

More information

Challenges in Developing Therapeutics in Partially Responsive and Treatment Resistant Depression Where do we go from here?

Challenges in Developing Therapeutics in Partially Responsive and Treatment Resistant Depression Where do we go from here? Challenges in Developing Therapeutics in Partially Responsive and Treatment Resistant Depression Where do we go from here? Heddie Martynowicz, MS Senior Director, Global Regulatory Affairs Janssen R &

More information

A vaccine for rheumatoid arthritis

A vaccine for rheumatoid arthritis A vaccine for rheumatoid arthritis Professor Ranjeny Thomas Founder and Director of Dendright Pty Limited Head, Autoimmunity Division, Diamantina Institute, The University of Queensland About Dendright

More information

Rx-360Upstream Supply Chain Security A Supplier Collaborative Approach to Mitigate Risk and Enhance Transparency

Rx-360Upstream Supply Chain Security A Supplier Collaborative Approach to Mitigate Risk and Enhance Transparency Rx-360Upstream Supply Chain Security A Supplier Collaborative Approach to Mitigate Risk and Enhance Transparency www.rx-360.org www.rx-360.org Presenter: Rob Welsh, VWR International, LLC VP Category Management

More information

Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth

Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth Brochure More information from http://www.researchandmarkets.com/reports/2640803/ Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine

More information

A new pharma launch paradigm: From one size fi ts all to a tailored product approach

A new pharma launch paradigm: From one size fi ts all to a tailored product approach A new pharma launch paradigm: From one size fi ts all to a tailored product approach Create an innovative Launch Factory by mapping your assets to four archetypes. By Michael Kunst, Rafael Natanek, Loic

More information

Clinical Trials OUTSOURCING & DEVELOPMENT

Clinical Trials OUTSOURCING & DEVELOPMENT Clinical Trials OUTSOURCING & DEVELOPMENT 2-3 rd December Singapore A clinical partnering event for outsourcing and development professionals and service providers in late phase clinical trials DRAFT AGENDA

More information

Report Brochure. Bispecific Antibody Therapeutics Market, 2013-2023. Copyright 2012 Banyan Wharf Consultants Ltd. Page 1

Report Brochure. Bispecific Antibody Therapeutics Market, 2013-2023. Copyright 2012 Banyan Wharf Consultants Ltd. Page 1 Report Brochure Bispecific Antibody Therapeutics Market, 2013-2023 Copyright 2012 Banyan Wharf Consultants Ltd. Page 1 This page is intentionally left blank Copyright 2013 Roots Analysis Private Ltd. All

More information

La ricerca clinica farmacologica nel paziente anziano: un costo inutile o un dato assente?

La ricerca clinica farmacologica nel paziente anziano: un costo inutile o un dato assente? La ricerca clinica farmacologica nel paziente anziano: un costo inutile o un dato assente? 57 Congresso Nazionale SIGG Società Italiana di Gerontologia e Geriatria Dr. Marco Scatigna Direttore Medico e

More information

meeting report on the review of applications for orphan designation

meeting report on the review of applications for orphan designation 13 June 2014 EMA/COMP/309595/2014 Committee for Orphan Medicinal Products (COMP) Committee for Orphan Medicinal Products (COMP) meeting report on the review of applications for orphan designation June

More information

Family Practitioners, General Practitioners, Internists, Physician Assistants, Nurse Practitioners, and Nurses

Family Practitioners, General Practitioners, Internists, Physician Assistants, Nurse Practitioners, and Nurses 36 th Annual Family Practice Review Online Planned and produced in accordance with the ACCME essentials. RELEASE DATE: February 25, 2013 EXPIRATION DATE: February 25, 2015 Physicians $750 Non-Physicians

More information

Small-Cell Lung Cancer Global Clinical Trials Review, H2, 2015

Small-Cell Lung Cancer Global Clinical Trials Review, H2, 2015 Brochure More information from http://www.researchandmarkets.com/reports/3398017/ Small-Cell Lung Cancer Global Clinical Trials Review, H2, 2015 Description: Small-Cell Lung Cancer Global Clinical Trials

More information

The Center for Clinical Trials of Drugs and Medical Devices

The Center for Clinical Trials of Drugs and Medical Devices Siberian State Medical University maintaining traditions to develop the medicine of the future The Center for Clinical Trials of Drugs and Medical Devices SIBERIAN STATE MEDICAL UNIVERSITY www.ssmu.ru

More information

1) SCOPE OF THE PROGRAM

1) SCOPE OF THE PROGRAM CALL FOR PROPOSALS 2015 CANADA/GERMANY JOINT PROGRAM DEADLINE: JANUARY 15 TH, 2016 1) SCOPE OF THE PROGRAM The main goal of the Canada/Germany joint program is to strengthen research in Canada and Germany

More information

Pharmaceutical Marketing Disclosures

Pharmaceutical Marketing Disclosures Pharmaceutical Marketing Disclosures July 1, 2007 June 30, 2008 Report of Vermont Attorney General William H. Sorrell April 2009 Prepared by staff of the Vermont Attorney General s Office: Wendy Morgan,

More information

Stakeholder Insight: Multiple Sclerosis Disease-modifying Efficacy and Side Effects Guide Treatment Choice

Stakeholder Insight: Multiple Sclerosis Disease-modifying Efficacy and Side Effects Guide Treatment Choice A Datamonitor report Stakeholder Insight: Multiple Sclerosis Disease-modifying Efficacy and Side Effects Guide Treatment Choice Published: Dec-06 Product Code: Providing you with: An overview of epidemiology,

More information

European Statistical Workshop (EFSPI/PSI): EMA Clinical Trial Data Transparency

European Statistical Workshop (EFSPI/PSI): EMA Clinical Trial Data Transparency European Statistical Workshop (EFSPI/PSI): EMA Clinical Trial Data Transparency Dr. Christoph Gerlinger 2013-08-22 Overview How it all began Current status EFSPI s Position EMA s draft Policy Aim of this

More information

Total Compensation Measurement. Global TCM Participants. Turkey

Total Compensation Measurement. Global TCM Participants. Turkey Total Compensation Measurement 2008 Global TCM Participants Turkey Turkey 2008 TCM Participants Summary Information The table below lists key summary information on the 67 TCM participants for 2008. Measure

More information

APPENDIX 1. Submissions and additional information received by the Committee. Submissions. 1 Bayer HealthCare Pharmaceuticals.

APPENDIX 1. Submissions and additional information received by the Committee. Submissions. 1 Bayer HealthCare Pharmaceuticals. APPENDIX 1 Submissions and additional information received by the Committee Submissions 1 Bayer HealthCare Pharmaceuticals 2 CanSpeak 3 Ms Kerry Drinkwater 4 Mr John Dowling 5 Mr David Prestridge 6 Mr

More information

Pharmaceutical industry

Pharmaceutical industry 8 th March 2016 Pharmaceutical industry 2015 Global ranking strategy decisive The annual company reporting season is always an exciting period. It is an ideal time to update our industry statistics and

More information

INCENTIVE COMPENSATION CONFERENCE

INCENTIVE COMPENSATION CONFERENCE Announcing the 2nd Annual ZS Associates INCENTIVE COMPENSATION CONFERENCE 08 September 23 24, 2008 Philadelphia, PA Incentive compensation greatly affects sales force motivation and morale. When designed

More information

全 球 多 发 性 硬 化 症 治 疗 市 场 研 究 报 告 Multiple Sclerosis Therapeutics - A Global Strategic Business Report

全 球 多 发 性 硬 化 症 治 疗 市 场 研 究 报 告 Multiple Sclerosis Therapeutics - A Global Strategic Business Report /wepdwukltuyot 全 球 多 发 性 硬 化 症 治 疗 市 场 研 究 报 告 Multiple Sclerosis Therapeutics - A Global Strategic Business Report 联 系 购 买 电 话 :010-82863480 公 司 名 称 : 佐 思 信 息 公 司 地 址 : 北 京 市 海 淀 区 苏 州 街 18 号 院 长 远 天

More information

Commercial Insight Osteoarthritis and Rheumatoid Arthritis

Commercial Insight Osteoarthritis and Rheumatoid Arthritis A Datamonitor In-Depth Analysis Commercial Insight Osteoarthritis and Rheumatoid Arthritis New Growth In A Mature Market Published: Jul-03 Product Code: DMHC1891 Why buy this analysis? Target current and

More information

2014 & 13 th Annual China Pharmaceutical, Life Science & Healthcare Industry Summit

2014 & 13 th Annual China Pharmaceutical, Life Science & Healthcare Industry Summit 2014 & 13 th Annual China Pharmaceutical, Life Science & Healthcare Industry Summit Addressing the most critical issues facing China s pharma & life science sector 10 th & 11 th April, 2014 Shanghai China

More information

Peking University Health Science Center Introduction

Peking University Health Science Center Introduction Peking University Health Science Center Introduction Content 1 2 3 4 General Information Medical Service Medical Education Medical Research 5 International Cooperation General Information A Brief History

More information

Product Profiles: Multiple Sclerosis - Gilenya Raises Bar for New Market Entrants

Product Profiles: Multiple Sclerosis - Gilenya Raises Bar for New Market Entrants Brochure More information from http://www.researchandmarkets.com/reports/1841621/ Product Profiles: Multiple Sclerosis - Gilenya Raises Bar for New Market Entrants Description: Introduction Beginning with

More information

The Gold Standard for Processing and Packaging

The Gold Standard for Processing and Packaging PACK EXPO Las Vegas Exhibitor Prospectus The Gold Standard for Processing and Packaging 2 O YEARS co-located with: packexpolasvegas.com/exhibit2015 A Reliable Source of Excellence When you exhibit at PACK

More information

Join our scientific talent community

Join our scientific talent community Join our scientific talent community There has never been a better time to be a part of Janssen Research & Development. We are at the forefront of healthcare leading, evolving and transforming it into

More information

Brochure More information from http://www.researchandmarkets.com/reports/3292678/

Brochure More information from http://www.researchandmarkets.com/reports/3292678/ Brochure More information from http://www.researchandmarkets.com/reports/3292678/ Asia Pacific (India, China, Australia, South Korea & Others) Insulin Market (Rapid Acting, Short Acting, Pre-Mixed, Long

More information

Osteoporosis Drug Development Moving Forward Public Workshop

Osteoporosis Drug Development Moving Forward Public Workshop Osteoporosis Drug Development Moving Forward Public Workshop November 4, 2015 Discussion Panel Members and Speakers Robert Adler, MD Chief, Endocrinology and Metabolism McGuire Veterans Affairs Medical

More information

Accelerating Drug & Clinical Trial Approvals in China & East Asia

Accelerating Drug & Clinical Trial Approvals in China & East Asia 25 28 March 2014 The Westin Beijing Chaoyang, Accelerating Drug & Clinical Trial Approvals in & East Asia What s New in 2014? Key Regulatory Update from the National Institute for Food & Drug Control,

More information

Digital Leaders Deal With a Range of Organizational Challenges

Digital Leaders Deal With a Range of Organizational Challenges May 22, 2014 OVERCOMING OBSTACLES TO DIGITAL TRANSFORMATION SUCCESS IN THE PHARMACEUTICAL INDUSTRY Digital Leaders Deal With a Range of Organizational Challenges by Tim van Tongeren with Dennis van Rooij

More information

LICENSING DEALS FORECASTS. The next five years and future deal values

LICENSING DEALS FORECASTS. The next five years and future deal values LICENSING DEALS FORECASTS The next five years and future deal values Sharon Finch, CEO years of successful partnering Outline Current deal landscape Deal values and trends Conclusions Based on Medius monthly

More information

Biopharmaceutical Raw Materials throughout the Product Lifecycle. Biosimilars and Biobetters Development & Production. www.ibclifesciences.

Biopharmaceutical Raw Materials throughout the Product Lifecycle. Biosimilars and Biobetters Development & Production. www.ibclifesciences. Monday Tuesday Programming: Wednesday Friday Programming: IBC s 18th International Process Validation, Monitoring & Control Supply Chain Management for Biopharmaceuticals Cold Chain Logistics and Distribution

More information

Pipeline Insight: Schizophrenia Asenapine; A future market leader?

Pipeline Insight: Schizophrenia Asenapine; A future market leader? A Datamonitor report Pipeline Insight: Schizophrenia Asenapine; A future market leader? Published: Jul-06 Product Code: DMHC2186 Providing you with: Detailed pipeline analysis for key products in development

More information

Commercial Perspectives: Multiple Sclerosis

Commercial Perspectives: Multiple Sclerosis A Datamonitor Report Commercial Perspectives: Multiple Sclerosis How to Find Opportunities in an Unremitting Market Published: Jun-04 Product Code: Providing you with: In-depth profiles of current market-leading

More information

PHARMACEUTICAL HUB SWITZERLAND ZURICH-ZUG-LUCERNE

PHARMACEUTICAL HUB SWITZERLAND ZURICH-ZUG-LUCERNE PHARMACEUTICAL HUB SWITZERLAND ZURICH-ZUG-LUCERNE TABLE OF CONTENTS Preface 4 Pharmaceutical Industry in Switzerland 6 Swiss Pharma Clusters 8 Growth Driver Pharmaceuticals 10 Zurich-Zug-Lucerne Region

More information